SuperworthStarling Oncology profit margin STLN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.
- Net margin, 12 months
- −6.2%
- Operating margin, 12 months
- −4.4%
- Net margin on a year earlier
- +9.3 pts
- Peer median
- 5.4%
Over the twelve months to Jun 30, 2026, Starling Oncology kept −6.2% of its revenue as net profit, with an operating margin of −4.4% and a gross margin of 15.7%.
The median for 10 hospital and care facility stocks of a similar size is 5.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −12.1% | −7.2% | 15.2% |
| FY2024 | −16.4% | −15.3% | 13.7% |
| FY2023 | −25.6% | −23.8% | 18.4% |
| FY2022 | 0.1% | −32.5% | 20.6% |
| FY2021 | −5.4% | −22.6% | 20.1% |
| FY2020 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −6.2% | +9.3 pts | −4.4% | |
| Q1 FY26 | −8.0% | +8.0 pts | −6.0% | |
| Q4 FY25 | −12.1% | +4.4 pts | −7.2% | |
| Q3 FY25 | −14.4% | +4.2 pts | −8.9% | |
| Q2 FY25 | −15.5% | +4.3 pts | −11.1% | |
| Q1 FY25 | −16.0% | +5.3 pts | −12.9% | |
| Q4 FY24 | −16.4% | +9.2 pts | −15.3% | |
| Q3 FY24 | −18.5% | +5.8 pts | −16.8% | |
| Q2 FY24 | −19.8% | +0.9 pts | −17.6% | |
| Q1 FY24 | −21.3% | −3.3 pts | −18.1% | |
| Q4 FY23 | −25.6% | −25.7 pts | −23.8% | |
| Q3 FY23 | −24.3% | −24.7 pts | −28.0% |
Against its peers
Companies in Medical - Care Facilities nearest Starling Oncology's size, closest first, today.
| Company | Profit margin |
|---|---|
| STLNStarling Oncology | −6.2% |
| SBCSBC Medical | 28.0% |
| OMDAOmada Health | 1.4% |
| VMDViemed Healthcare | 4.8% |
| USPHU S Physical Therapy | 4.0% |
| PNTGPennant | 2.9% |
| ARDTArdent Health | 1.2% |
| HCSGHealthcare Services | 6.6% |
| PGNYProgyny | 6.0% |
| ADUSAddus HomeCare | 7.1% |
| MDPediatrix Medical | 9.0% |
| Peer median | 5.4% |
Where Starling Oncology ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Starling Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.